Company Dynamics Update
On March 28, 2025, the Wuhai Municipal Ecology and Environment Bureau released the public notice of the approval opinion for the environmental impact assessment (EIA) regarding Inner Mongolia Yize Pharmaceutical Co., Ltd.’s (Yize Pharmaceutical) production project for vitamin B6 and other pharmaceutical intermediates. This milestone highlights Yize Pharmaceutical’s ongoing expansion and transformation efforts within the pharmaceutical sector.
Project Scope and Investment Overview
The project is situated in Wuda Industrial Park, Wuhai City, Inner Mongolia Autonomous Region, and is characterized as a reconstruction/renovation and expansion initiative. Key project details include:
- Total Investment: USD 6.85 million (RMB 49.18 million)
- Environmental Protection Investment: USD 83,594.57 (RMB 600,000), representing 1.22% of the total investment
The project encompasses:
- 1,500 t/a creatine monohydrate production
- 1,500 t/a phenylphosphothiamine and intermediates production
- 1,000 t/a crude vitamin B6 production and intermediates including heptane, oxazole, and oxalic acid
Project Development Background
Initially, the EIA for the existing project involved the construction of 10 production lines. However, during the acceptance phase, only 9 were completed, and the planned chloromethyl carbonate isopropyl ester production line was canceled due to changing market dynamics.
Due to declining demand for cytosine and aminopropionic acid products, Yize Pharmaceutical discontinued these product lines. To optimize resource utilization, the company is repurposing idle equipment to support the production of creatine monohydrate, phenylphosphothiamine, and vitamin B6, demonstrating adaptability and market responsiveness.
Company Background
Established on August 6, 2019, Yize Pharmaceutical is a subsidiary of Shanghai Chuangnuo Pharmaceutical Group. It specializes in the research, development, production, and sales of chemically synthesized pharmaceutical raw materials, intermediates, and active pharmaceutical ingredients (APIs).
Industry Outlook
The approval of Yize Pharmaceutical’s EIA reflects the increasing demand for pharmaceutical-grade vitamins and intermediates. The project is expected to bolster China’s position in the global vitamin B6 supply chain, while also reinforcing the industry’s commitment to sustainable development and compliance with environmental standards.
Accelerate Your Business with China Informatics
Partner with China Informatics for:
- Real-time pharmaceutical market analysis to seize emerging opportunities.
- Regulatory affairs intelligence on pharmaceutical project approvals across China.
- In-depth insights into company dynamics and manufacturing expansions in the vitamin and API sectors.
Our expert solutions help you move faster and lead your industry. Connect with China Informatics today.
